Drug pricing policies in one of the largest drug manufacturing nations in the world: Are affordability and access a cause for concern?
Saved in:
Main Authors: | Akram Ahmad (Author), Muhammad Umair Khan (Author), Isha Patel (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2015-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Price, availability and affordability of medicines
by: Brenda S. Mhlanga, et al.
Published: (2014) -
Access to essential medicines for diabetes care: availability, price, and affordability in central Ethiopia
by: Hachalu Dugasa Deressa, et al.
Published: (2024) -
Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala
by: Anson Angela, et al.
Published: (2012) -
Patients' access to drugs with rebates in Switzerland - Empirical analysis and policy implications for drug pricing in Europe
by: David L Carl, BA, et al.
Published: (2021) -
The impact of level of documentation on the accessibility and affordability of new drugs in Norway
by: Gro Live Fagereng, et al.
Published: (2024)